Cargando…

Corticosteroid treatment for early acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials

BACKGROUND: The effect of corticosteroid treatment on survival outcome in early acute respiratory distress syndrome (ARDS) is still debated. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the efficacy of prolonged corticosteroid therapy in early A...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirano, Yohei, Madokoro, Shunsuke, Kondo, Yutaka, Okamoto, Ken, Tanaka, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720037/
https://www.ncbi.nlm.nih.gov/pubmed/33722302
http://dx.doi.org/10.1186/s40560-020-00510-y
_version_ 1783619791547793408
author Hirano, Yohei
Madokoro, Shunsuke
Kondo, Yutaka
Okamoto, Ken
Tanaka, Hiroshi
author_facet Hirano, Yohei
Madokoro, Shunsuke
Kondo, Yutaka
Okamoto, Ken
Tanaka, Hiroshi
author_sort Hirano, Yohei
collection PubMed
description BACKGROUND: The effect of corticosteroid treatment on survival outcome in early acute respiratory distress syndrome (ARDS) is still debated. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the efficacy of prolonged corticosteroid therapy in early ARDS. METHODS: We assessed the MEDLINE, Cochrane Central Register of Controlled Trials, and Web of Science databases from inception to August 1, 2020. We included RCTs that compared prolonged corticosteroid therapy with control treatment wherein the intervention was started within 72 h of ARDS diagnosis. Two investigators independently screened the citations and conducted the data extraction. The primary outcomes were all-cause 28- or 30-day mortality and 60-day mortality. Several endpoints such as ventilator-free days and adverse events were set as the secondary outcomes. DerSimonian-Laird random-effects models were used to report pooled odds ratios (ORs). RESULTS: Among the 4 RCTs included, all referred to the all-cause 28- or 30-day mortality. In the corticosteroid group, 108 of 385 patients (28.1%) died, while 139 of 357 (38.9%) died in the control group (pooled OR, 0.61; 95% confidence interval [CI], 0.44–0.85). Three RCTs mentioned the all-cause 60-day mortality. In the corticosteroid group, 78 of 300 patients (26.0%) died, while 101 of 265 (38.1%) died in the control group (pooled OR, 0.57; 95% CI, 0.40–0.83). For secondary outcomes, corticosteroid treatment versus control significantly prolonged the ventilator-free days (4 RCTs: mean difference, 3.74; 95% CI, 1.53–5.95) but caused hyperglycemia (3 RCTs: pooled OR, 1.52; 95% CI, 1.04–2.21). CONCLUSIONS: Prolonged corticosteroid treatment in early ARDS improved the survival outcomes. TRIAL REGISTRATION: PROSPERO, CRD42020195969 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40560-020-00510-y.
format Online
Article
Text
id pubmed-7720037
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77200372020-12-07 Corticosteroid treatment for early acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials Hirano, Yohei Madokoro, Shunsuke Kondo, Yutaka Okamoto, Ken Tanaka, Hiroshi J Intensive Care Research BACKGROUND: The effect of corticosteroid treatment on survival outcome in early acute respiratory distress syndrome (ARDS) is still debated. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the efficacy of prolonged corticosteroid therapy in early ARDS. METHODS: We assessed the MEDLINE, Cochrane Central Register of Controlled Trials, and Web of Science databases from inception to August 1, 2020. We included RCTs that compared prolonged corticosteroid therapy with control treatment wherein the intervention was started within 72 h of ARDS diagnosis. Two investigators independently screened the citations and conducted the data extraction. The primary outcomes were all-cause 28- or 30-day mortality and 60-day mortality. Several endpoints such as ventilator-free days and adverse events were set as the secondary outcomes. DerSimonian-Laird random-effects models were used to report pooled odds ratios (ORs). RESULTS: Among the 4 RCTs included, all referred to the all-cause 28- or 30-day mortality. In the corticosteroid group, 108 of 385 patients (28.1%) died, while 139 of 357 (38.9%) died in the control group (pooled OR, 0.61; 95% confidence interval [CI], 0.44–0.85). Three RCTs mentioned the all-cause 60-day mortality. In the corticosteroid group, 78 of 300 patients (26.0%) died, while 101 of 265 (38.1%) died in the control group (pooled OR, 0.57; 95% CI, 0.40–0.83). For secondary outcomes, corticosteroid treatment versus control significantly prolonged the ventilator-free days (4 RCTs: mean difference, 3.74; 95% CI, 1.53–5.95) but caused hyperglycemia (3 RCTs: pooled OR, 1.52; 95% CI, 1.04–2.21). CONCLUSIONS: Prolonged corticosteroid treatment in early ARDS improved the survival outcomes. TRIAL REGISTRATION: PROSPERO, CRD42020195969 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40560-020-00510-y. BioMed Central 2020-12-07 /pmc/articles/PMC7720037/ /pubmed/33722302 http://dx.doi.org/10.1186/s40560-020-00510-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Hirano, Yohei
Madokoro, Shunsuke
Kondo, Yutaka
Okamoto, Ken
Tanaka, Hiroshi
Corticosteroid treatment for early acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials
title Corticosteroid treatment for early acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials
title_full Corticosteroid treatment for early acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials
title_fullStr Corticosteroid treatment for early acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials
title_full_unstemmed Corticosteroid treatment for early acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials
title_short Corticosteroid treatment for early acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials
title_sort corticosteroid treatment for early acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720037/
https://www.ncbi.nlm.nih.gov/pubmed/33722302
http://dx.doi.org/10.1186/s40560-020-00510-y
work_keys_str_mv AT hiranoyohei corticosteroidtreatmentforearlyacuterespiratorydistresssyndromeasystematicreviewandmetaanalysisofrandomizedtrials
AT madokoroshunsuke corticosteroidtreatmentforearlyacuterespiratorydistresssyndromeasystematicreviewandmetaanalysisofrandomizedtrials
AT kondoyutaka corticosteroidtreatmentforearlyacuterespiratorydistresssyndromeasystematicreviewandmetaanalysisofrandomizedtrials
AT okamotoken corticosteroidtreatmentforearlyacuterespiratorydistresssyndromeasystematicreviewandmetaanalysisofrandomizedtrials
AT tanakahiroshi corticosteroidtreatmentforearlyacuterespiratorydistresssyndromeasystematicreviewandmetaanalysisofrandomizedtrials